A pilot study of bendamustine in advanced bile duct cancer

Anti-Cancer Drugs

Volumn 18, Issue 6, 2007, Pages 697-702

  Schoppmeyer, Konrad ^a   Kreth, Florian ^b   Wiedmann, Marcus ^a   Mössner, Joachim ^a   Preiss, Rainer ^a   Caca, Karel ^c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c KLINIKUM LUDWIGSBURG   (Germany)

Author keywords

Bendamustine; Biliary drainage; Extrahepatic bile duct cancer; Liver function; Toxicity

Indexed keywords

BENDAMUSTINE;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ANOREXIA; ARTICLE; BILE DUCT CANCER; BIOCHEMISTRY; BLOOD EXAMINATION; CARDIOTOXICITY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; FATIGUE; FEMALE; FEVER; HUMAN; LIVER FUNCTION; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; THORAX RADIOGRAPHY; XEROSTOMIA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER FUNCTION TESTS; MALE; METABOLIC DETOXICATION, PHASE II; MIDDLE AGED; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; PILOT PROJECTS;

EID: 34548303943     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32803d36e6     Document Type: Article

References (41)

1. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48:816-820.
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33:1353-1357.
3. West J, Wood H, Logan RFA, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006; 94:1751-1758.
4. Robert-Koch-Institut: http://www.rki.de/cln_006/nn_352008/DE/Content/GBE/ DachdokKrebs/krebs__node.html__nnn = true.
5. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75 (1 Suppl):171-190.
6. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224:463-473.
7. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234:507-519.
8. Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma - palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg 2006; 244:230-239.
9. Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999; 230:808-819.
10. Nordback IH, Pitt HA, Coleman J, Venbrux AC, Dooley WC, Yeu NN, et al. Unresectable hilar cholangiocarcinoma: percutaneous versus operative palliation. Surgery 1994; 115:597-603.
11. Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet 1994; 344:1655-1660.
12. Ortner MA, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, et al. Succesful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125:1355- 1363.
13. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann J. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100:2426-2430.
14. Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000; 31:291-298.
15. Dumoulin FL, Gerhardt T, Fuchs S, Scheurlen C, Neubrand M, Layer G, et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003; 57:860-867.
16. Wiedmann M, Berr F, Schiefke I, Witzigmann H, Kohlhaw K, Mossner J, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004; 60:68-75.
17. Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, Rauws EAW, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003; 27:173-179.
18. GonzalezGonzalez D, Gouma DJ, Rauws EA, van Gulik TM, Bosma A, Koedooder C. Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol 1999; 10 (Suppl 4):215-220.
19. Kamada T, Saitou H, Takamura A, Nojima T, Okushiba SI. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 1996; 34:767-774.
20. Kuvshinoff BW, Armstrong JG, Fong Y, Schupak K, Getradjman G, Heffernan N, et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg 1995; 82:1522-1525.
21. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600.
22. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92:1650-1654.
23. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15:1339-1343.
24. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23:2332-2338.
25. Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomized phase II trial. Ann Oncol 2004; 15:478-483.
26. Nehls O, Oettle H, Hartmann JT, Hofheinz R, Hochhaus A, Makowski M, et al. A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas. Proc Am Soc Clin Oncol 2004; 23:A4091.
27. Reyes-Vidal JM, Gallardo J, Yañez E, Rosas J, Palma M, Cerda B, et al. Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: results of the phase II GOCCHI study 2000-2013. Proc Am Soc Clin Oncol 2003; 22:A1095.
28. Hartmann M, Zimmer CH. Investigation of cross-link formation in DNA by the alkylating cytostatika IMET 3106, 3393, and 3943. Biochim Biophys Acta 1972; 287:386-389.
29. Strumberg D, Harstick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996; 7:415-421.
30. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002; 128:603-609.
31. Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol. 2006; 132:105-112.
32. Kath R, Blumenstengel K, Fricke HJ, Höffken K. Bendamustine montherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001; 127:48-54.
33. Ponisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132:205-212.
34. Von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005; 16:871-877.
35. Weidmann E, Kim SZ, Rost A, Schuppert H, Seipelt G, Hoelzer D, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1285-1289.
36. Matthias M, Preiss R, Sohr R, Possinger K. Pharmacokinetics of bendamustine in patients with malignant tumors. Proc Am Soc Clin Oncol 1995; 14 [abstract 1476].
37. Teichert J, Sohr R, Baumann F, Hennig L, Merkle K, Caca K, et al. Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005; 33:984-992.
38. Sobin LH, Wittekind C. UICC: TNM classification of malignant tumours. New York: Wiley Liss; 2002.
39. Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998; 47:354-362.
40. De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53:547-553.
41. Zech CJ, Schoenberg SO, Reiser M, Helmberger T. Cross-sectional imaging of biliary tumors: current clinical status and future developments. Eur Radiol 2004; 14:1174-1187.